193756-44-4

Basic information

• Product Name: N-(2,3-Dihydro-1H-inden-2-yl)-2,2,2-trifluoroacetamide
• Synonyms: N-(2,3-Dihydro-1H-inden-2-yl)-2,2,2-trifluoroacetamide
• CAS NO: 193756-44-4
• Molecular Formula: C11H10F3NO
• Molecular Weight: 229.1984096
• Mol File: 193756-44-4.mol
• Article Data: 7

Chemical Properties

• Melting Point: 153-155℃
• Boiling Point: 319℃
• Flash Point: 147℃
• Appearance: /
• Density: 1.31
• PKA: 11.04±0.20(Predicted)
• CAS DataBase Reference: N-(2,3-Dihydro-1H-inden-2-yl)-2,2,2-trifluoroacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,3-Dihydro-1H-inden-2-yl)-2,2,2-trifluoroacetamide(193756-44-4)
• EPA Substance Registry System: N-(2,3-Dihydro-1H-inden-2-yl)-2,2,2-trifluoroacetamide(193756-44-4)

Safety Data

• Hazardous Substances Data: 193756-44-4(Hazardous Substances Data)

Usage

Description

N-(2,3-Dihydro-1H-inden-2-yl)-2,2,2-trifluoroacetamide is an organic compound that serves as an intermediate in the synthesis of hydroxyquinoline substituted aminoindans. These aminoindans are known to act as β2-adrenoceptor agonists, which have potential applications as ultralong-acting bronchodilators.

Uses

Used in Pharmaceutical Industry:
N-(2,3-Dihydro-1H-inden-2-yl)-2,2,2-trifluoroacetamide is used as an intermediate in the synthesis of hydroxyquinoline substituted aminoindans for the development of ultralong-acting bronchodilators. These bronchodilators are essential in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), as they help to relax the muscles in the airways and improve breathing.

Upstream product

• 2338-18-3 2-aminoindane hydrochloride 
• 76-05-1 trifluoroacetic acid 
• 2975-41-9 2,3-dihydro-1H-inden-2-amine 
• 407-25-0 trifluoroacetic anhydride 
• 685-27-8 2,2,2-trifluoro-N-methyl-N-(2,2,2-trifluoroacetyl)acetamide 
• 383-63-1 ethyl trifluoroacetate, 

Downstream Products

• 601487-87-0 N-(5-acetyl-2,3-dihydro-1H-inden-2-yl)-2,2,2-trifluoroacetamide 
• 312753-53-0 5,6-diethyl-2,3-dihydro-1H-inden-2-amine hydrochloride 
• 601487-88-1 N-(5-ethyl-2,3-dihydro-1H-inden-2-yl)-2,2,2-trifluoroacetamide 
• 312753-70-1 5,6-diethyl-2,3-dihydro-1H-inden-2-amine 

Relevant articles and documents

An efficient and economical synthesis of 5,6-diethyl-2,3-dihydro-1H-inden- 2-amine hydrochloride

An efficient and economical synthesis of 5,6-diethyl-2,3-dihydro-1H-inden- 2-amine hydrochloride (1) utilizing 2-aminoindan as a cheap and commercially readily available starting material is described. The newly developed synthesis involves six-steps with 49% overall yield, and it introduces two ethyl groups at the 5- and 6-positions via sequential regioselective Friedel-Crafts acetylations and hydrogenations of N-protected-2-aminoindan. The Friedel-Crafts acetylations can be carried out neat with high regioselectivity using acetyl chloride as the reagent as well as the solvent, thus avoiding the use of halogenated solvents.

THIENOPYRIMIDONE COMPOUND

The present invention relates to a compound represented by the formula: wherein Ar is an optionally substituted ring; A is a spacer having a main chain of 1 to 4 atoms; B is a bond, a C1-10 alkylene group or an oxygen atom; R3 and R5 are each independently a hydrogen atom or a substituent; R4 is an optionally substituted cyclic group or an optionally substituted C1-10 alkyl group; and R1 and R2 are each independently a hydrogen atom or a substituent, or R1 and R2 or R1 and B are bonded to form an optionally substituted nitrogen-containing heterocycle, or R1 and Ar are bonded to form an optionally substituted nitrogen-containing fused heterocycle, or a salt thereof. The thienopyrimidone compound of the present invention has a superior melanin-concentrating hormone receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of obesity and the like.

HETEROCYCLIC SUBSTITUTED INDANE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA

This invention relates to compounds of the formula (I) wherein J, M, G, m, X, R', R2, R4, R5, R6, R7, R8, R9, Y, n, z, and R" are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system and other disorders.